1. Home
  2. HEPA vs SPGC Comparison

HEPA vs SPGC Comparison

Compare HEPA & SPGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HEPA
  • SPGC
  • Stock Information
  • Founded
  • HEPA 2013
  • SPGC 2018
  • Country
  • HEPA United States
  • SPGC United States
  • Employees
  • HEPA N/A
  • SPGC N/A
  • Industry
  • HEPA Biotechnology: Pharmaceutical Preparations
  • SPGC
  • Sector
  • HEPA Health Care
  • SPGC
  • Exchange
  • HEPA Nasdaq
  • SPGC Nasdaq
  • Market Cap
  • HEPA 4.1M
  • SPGC 3.6M
  • IPO Year
  • HEPA N/A
  • SPGC 2023
  • Fundamental
  • Price
  • HEPA $0.57
  • SPGC $0.32
  • Analyst Decision
  • HEPA Hold
  • SPGC
  • Analyst Count
  • HEPA 1
  • SPGC 0
  • Target Price
  • HEPA N/A
  • SPGC N/A
  • AVG Volume (30 Days)
  • HEPA 27.6K
  • SPGC 2.3M
  • Earning Date
  • HEPA 11-14-2024
  • SPGC 11-14-2024
  • Dividend Yield
  • HEPA N/A
  • SPGC N/A
  • EPS Growth
  • HEPA N/A
  • SPGC N/A
  • EPS
  • HEPA N/A
  • SPGC N/A
  • Revenue
  • HEPA N/A
  • SPGC $2,491,000.00
  • Revenue This Year
  • HEPA N/A
  • SPGC $899.43
  • Revenue Next Year
  • HEPA N/A
  • SPGC $49.83
  • P/E Ratio
  • HEPA N/A
  • SPGC N/A
  • Revenue Growth
  • HEPA N/A
  • SPGC 840.00
  • 52 Week Low
  • HEPA $0.48
  • SPGC $0.27
  • 52 Week High
  • HEPA $3.72
  • SPGC $9.17
  • Technical
  • Relative Strength Index (RSI)
  • HEPA 39.66
  • SPGC 15.09
  • Support Level
  • HEPA $0.48
  • SPGC $0.26
  • Resistance Level
  • HEPA $0.66
  • SPGC $0.38
  • Average True Range (ATR)
  • HEPA 0.06
  • SPGC 0.08
  • MACD
  • HEPA -0.01
  • SPGC -0.13
  • Stochastic Oscillator
  • HEPA 32.88
  • SPGC 4.12

About HEPA Hepion Pharmaceuticals Inc.

Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan-cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.

About SPGC Sacks Parente Golf Inc.

Sacks Parente Golf Inc is a technology-forward golf company, with a growing portfolio of golf products, including putting instruments, golf shafts, golf grips, and other golf-related products. It designs, manufactures, and sells technology-forward, golf equipment, which is comprised of putting instruments, golf shafts, golf grips, and related product groups. It designs its golf products to fit golfers of all skill levels, amateur and professional. Its business segments currently include, golf putting instruments, golf shafts, and golf related products.

Share on Social Networks: